ZYM-002

ZYM-002 is a small molecule therapeutic candidate developed by Zymedyne Therapeutics for the treatment of chronic and neuropathic pain. It acts by selectively disrupting the protein-protein interaction between the deubiquitinating enzyme USP5 and the Cav3.2 T-type calcium channel. In chronic pain states, USP5 is pathologically upregulated and binds to Cav3.2, preventing its degradation and leading to aberrant channel upregulation and enhanced pain signaling. By disrupting this interaction, ZYM-002 promotes the degradation of Cav3.2 channels, thereby normalizing channel expression and providing analgesia without the adverse effects or tolerance associated with traditional pain medications like opioids.